| Synonym |
| Thai / English name |
Part Used : ผลActivity : CYTOCHROME P-450 INHIBITIONSolvent/Active Compound : Trikatu laboratory formulation / DMSOType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 micrograms/mLDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Results: Extract of the formulations and its ingredients had higher solubility in DMSO than ethanol. It illustrated the highest percentage of inhibition: 37.54+/-3.12% (Trikatu marketed formulation), 35.12+/-2.31% (Trikatu laboratory formulation), 33.23+/-2.56% (6-gingerol), 31.36+/-3.42% (piperine), 17.35+/+1.50% (Zingiber officinale), 20.21+/-1.86% (Piper longum), and 16.67+/-2.83% (Piper nigrum). Lowest inhibition (24.81+/-2.57% and 26.38+/-2.57%) of piperine and 6-gingerol was observed with ethanol.Note : Type of experiment: rat liver microsomes. The amount of 6-gingerol present in extract of Zingiber officinal, Trikatumarketed formulation and Trikatu laboratory formulation was estimated to be about 6.21+/-1.03%, 5.3+/-1.21% and 4.95+/-2.34% (w/w), respectively. Piperine was found to be 7.31+/-2.36% (Piper longum), 8.41+/-2.54% (Piper nigrum), 7.89+/-2.12% (Trikatu marketed formulation) and 6.70+/-2.13% (w/w) (Trikatu laboratory formulation).
Part Used : ไม่ระบุActivity : CYTOCHROME P-450 INHIBITIONSolvent/Active Compound : 6-gingerolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 5 microgram/mlDuration : -Type of interaction : PharmacokineticsInteraction with drug : AstemizoleDose/Conc.(drug) : 1 micromolarResult : PositiveRemark : 6-gingerol inhibited the CYP2J2 catalyzed astemizole with 27% inhibition.
Part Used : ไม่ระบุActivity : CYTOCHROME P-450 INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : non specifiedN(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Ginger fraction, use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P 450 3A4, CYP3A4) for positive influencing the oral bioavailablity and pharmacokinetics of active substance.Note : Data incomplete from abstract
Part Used : ไม่ระบุActivity : CYTOCHROME P-450 INHIBITIONSolvent/Active Compound : ethanolType of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 100 mg/kgDuration : 21 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : The activity of drug metabolizing enzyme; CYP-450 was significant decreased by pre-treatment with ethanolic extract of ginger especially with the dose of 100 mg/kg. BW.Note : Animals were assigned to 1 of 5 groups: control group; bromobenzene (460 mg/kg BW) alone, three animal groups 3-5 treated with different doses of ethanolic ginger extract (100, 200, 300 mg/kg BW, respectively) Bromobenzene (BB) induced hepatotoxicity (from its metabolites)
Part Used : ไม่ระบุActivity : CYTOCHROME P-450 INHIBITIONSolvent/Active Compound : ethanolType of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 200 mg/kgDuration : 21 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : The activity of drug metabolizing enzyme; CYP-450 was significant decreased by pre-treatment with ethanolic extract of ginger especially with the dose of 100 mg/kg. BW.Note : Animals were assigned to 1 of 5 groups: control group; bromobenzene (460 mg/kg BW) alone, three animal groups 3-5 treated with different doses of ethanolic ginger extract (100, 200, 300 mg/kg BW, respectively) Bromobenzene (BB) induced hepatotoxicity (from its metabolites)
Part Used : ไม่ระบุActivity : CYTOCHROME P-450 INHIBITIONSolvent/Active Compound : -Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 300 mg/kgDuration : 21 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : The activity of drug metabolizing enzyme; CYP-450 was significant decreased by pre-treatment with ethanolic extract of ginger especially with the dose of 100 mg/kg. BW.Note : Animals were assigned to 1 of 5 groups: control group; bromobenzene (460 mg/kg BW) alone, three animal groups 3-5 treated with different doses of ethanolic ginger extract (100, 200, 300 mg/kg BW, respectively) Bromobenzene (BB) induced hepatotoxicity (from its metabolites)
